Literature DB >> 11585581

Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.

I Mizuta1, M Ohta, K Ohta, M Nishimura, E Mizuta, S Kuno.   

Abstract

Riluzole is an antiexcitotoxic agent used for the treatment of amyotrophic lateral sclerosis, and reported to have neuroprotective effects in animal models of Parkinson's disease, Huntington's disease and brain ischemia. We investigated the effects of riluzole on synthesis of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in cultured mouse astrocytes. The protein and mRNA levels were measured by enzyme-linked immunosorbent assay and semiquantitative reverse transcription-polymerase chain reaction, respectively. Treatment with riluzole at 100 microg/ml (426 microM) for 24 h increased the contents of NGF, BDNF, and GDNF in the culture medium 109-fold, 2.0-fold and 3.1-fold over the control, respectively. The drug-induced relative mRNA levels of NGF, BDNF, and GDNF were 7.3-fold at 2 h, 2.1-fold at 4 h, and 1.9-fold at 2 h, respectively. These results indicate that riluzole stimulates synthesis of NGF, BDNF and GDNF in cultured astrocytes. Riluzole might exert neuroprotective effects, at least in part, via stimulation of neurotrophic factors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585581     DOI: 10.1016/s0304-3940(01)02098-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  46 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 3.  Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach.

Authors:  Rodrigo Machado-Vieira; Marcio G Soeiro-De-Souza; Erica M Richards; Antonio L Teixeira; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-02       Impact factor: 4.132

4.  Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier.

Authors:  Fumitaka Shimizu; Yasuteru Sano; Kazuyuki Saito; Masa-aki Abe; Toshihiko Maeda; Hiroyo Haruki; Takashi Kanda
Journal:  Neurochem Res       Date:  2011-10-16       Impact factor: 3.996

Review 5.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

Review 6.  New advances on glial activation in health and disease.

Authors:  Kim Mai Lee; Andrew G MacLean
Journal:  World J Virol       Date:  2015-05-12

Review 7.  Don't forget astrocytes when targeting Alzheimer's disease.

Authors:  Jessica S Sadick; Shane A Liddelow
Journal:  Br J Pharmacol       Date:  2019-02-19       Impact factor: 8.739

Review 8.  High content analysis in amyotrophic lateral sclerosis.

Authors:  Federica Rinaldi; Dario Motti; Laura Ferraiuolo; Brian K Kaspar
Journal:  Mol Cell Neurosci       Date:  2016-12-11       Impact factor: 4.314

Review 9.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

Authors:  Sanjay J Mathew; James W Murrough; Marije aan het Rot; Katherine A Collins; David L Reich; Dennis S Charney
Journal:  Int J Neuropsychopharmacol       Date:  2009-03-17       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.